We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Elevance Health Inc. operates as a health benefits company. It supports consumers, families and communities across the entire care journey connecting to the care, support and resources to lead healthier lives. Elevance Health Inc., formerly known as Anthem Inc., is based in Indianapolis, Indiana.
- Recent ELV Stock Price: $533.73
- Yearly Gain for ELV stock: 15.30%
- Market Cap for ELV stock: $124.05B
- P/E Ratio for ELV stock: 20.14
Will ELV's stock price go up? Is there an accurate ELV stock forecast available?
TipRanks.com reports that Elevance Health Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $603.00. The target pricing ranges from a high ELV forecast of $621 down to a low forecast of $585. Elevance Health Inc. (ELV)’s last closing stock price was $533.73 which would put the average price target at 12.98% upside.
In addition, TradingView issued a rating for ELV stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on ELV stock.
Other analysts covering ELV include:
- David Windley of Jefferies issued a Buy rating with the price target of $604 on 5 days ago
- A.J. Rice of UBS issued a Buy rating with the price target of $605 on 5 days ago
- Kevin Fischbeck of Bank of America Securities issued a Buy rating with the price target of $621 on 5 days ago
- Steve Baxter of Wells Fargo issued a Buy rating with the price target of $600 on 5 days ago
If you are wondering if ELV is a good stock to buy, here are 3rd party ratings for ELV stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (91 out of 252)
What is the sentiment on the street regarding Elevance Health Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ELV stock: Bullish
- Blogger Consensus for ELV stock:
- Media Buzz for ELV stock: Strong Buy
- Insider Signal for ELV stock: Buying
- Investor Sentiment for ELV stock: Positive
- Hedge Fund signal for ELV stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on ELV stock including scouring the social networks like ELV StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ELV stock chart >>
Summary: Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
- Recent NBIX Stock Price: $138.97
- Yearly Gain for NBIX stock: 34.19%
- Market Cap for NBIX stock: $13.83B
- P/E Ratio for NBIX stock: 56.26
Will NBIX's stock price go up? Is there an accurate NBIX stock forecast available?
TipRanks.com reports that Neurocrine Biosciences, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $164.60. The target pricing ranges from a high NBIX forecast of $200 down to a low forecast of $136. Neurocrine Biosciences, Inc. (NBIX)’s last closing stock price was $138.97 which would put the average price target at 18.44% upside.
In addition, TradingView issued a rating for NBIX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on NBIX stock.
Other analysts covering NBIX include:
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $150 on 18 hours ago
- Akash Tewari of Jefferies issued a Buy rating with the price target of $182 on 1 day ago
- Chris Shibutani of Goldman Sachs issued a Buy rating with the price target of $155 on 1 day ago
- Brian Abrahams of RBC Capital issued a Hold rating with the price target of $136 on 1 day ago
If you are wondering if NBIX is a good stock to buy, here are 3rd party ratings for NBIX stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: n/a Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Bottom 42% (147 out of 252)
What is the sentiment on the street regarding Neurocrine Biosciences, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for NBIX stock: Bullish
- Blogger Consensus for NBIX stock:
- Media Buzz for NBIX stock: Strong Buy
- Insider Signal for NBIX stock: Balanced
- Investor Sentiment for NBIX stock: Positive
- Hedge Fund signal for NBIX stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on NBIX stock including scouring the social networks like NBIX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NBIX stock chart >>
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
- Recent BIIB Stock Price: $201.99
- Yearly Gain for BIIB stock: -31.07%
- Market Cap for BIIB stock: $29.36B
- P/E Ratio for BIIB stock: 25.31
Will BIIB's stock price go up? Is there an accurate BIIB stock forecast available?
TipRanks.com reports that Biogen Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $271.00. The target pricing ranges from a high BIIB forecast of $294 down to a low forecast of $260. Biogen Inc. (BIIB)’s last closing stock price was $201.99 which would put the average price target at 34.17% upside.
In addition, TradingView issued a rating for BIIB stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on BIIB stock.
Other analysts covering BIIB include:
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $260 on 18 hours ago
- Geoff Meacham of Bank of America Securities issued a Hold rating with the price target of $260 on 1 day ago
- Jay Olson of Oppenheimer issued a Buy rating with the price target of $270 on 2 days ago
If you are wondering if BIIB is a good stock to buy, here are 3rd party ratings for BIIB stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 31% (78 out of 252)
What is the sentiment on the street regarding Biogen Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for BIIB stock: Bullish
- Blogger Consensus for BIIB stock:
- Media Buzz for BIIB stock: Strong Buy
- Insider Signal for BIIB stock: Selling
- Investor Sentiment for BIIB stock: Negative
- Hedge Fund signal for BIIB stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on BIIB stock including scouring the social networks like BIIB StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BIIB stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================